WO2023016450A1 - 抗tigit抗体及其用途 - Google Patents
抗tigit抗体及其用途 Download PDFInfo
- Publication number
- WO2023016450A1 WO2023016450A1 PCT/CN2022/111145 CN2022111145W WO2023016450A1 WO 2023016450 A1 WO2023016450 A1 WO 2023016450A1 CN 2022111145 W CN2022111145 W CN 2022111145W WO 2023016450 A1 WO2023016450 A1 WO 2023016450A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antigen
- binding fragment
- cancer
- seq
- Prior art date
Links
- 230000027455 binding Effects 0.000 claims abstract description 177
- 238000009739 binding Methods 0.000 claims abstract description 164
- 239000000427 antigen Substances 0.000 claims abstract description 152
- 108091007433 antigens Proteins 0.000 claims abstract description 149
- 102000036639 antigens Human genes 0.000 claims abstract description 149
- 239000012634 fragment Substances 0.000 claims abstract description 135
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims abstract description 91
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims abstract description 76
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 29
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 27
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 27
- 239000003446 ligand Substances 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 117
- 241000282414 Homo sapiens Species 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 52
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 49
- 238000006467 substitution reaction Methods 0.000 claims description 41
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 32
- 108010048507 poliovirus receptor Proteins 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 20
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 19
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 17
- 238000007792 addition Methods 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 16
- 230000037430 deletion Effects 0.000 claims description 16
- 241000282567 Macaca fascicularis Species 0.000 claims description 14
- 210000000822 natural killer cell Anatomy 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102100035488 Nectin-2 Human genes 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 229960002685 biotin Drugs 0.000 claims description 9
- 235000020958 biotin Nutrition 0.000 claims description 9
- 239000011616 biotin Substances 0.000 claims description 9
- 210000004602 germ cell Anatomy 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical class [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 7
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 7
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 7
- 229910052707 ruthenium Inorganic materials 0.000 claims description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 6
- -1 acridine ester compounds Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 108091006047 fluorescent proteins Proteins 0.000 claims description 6
- 102000034287 fluorescent proteins Human genes 0.000 claims description 6
- 230000033581 fucosylation Effects 0.000 claims description 6
- 210000002865 immune cell Anatomy 0.000 claims description 6
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 102000006471 Fucosyltransferases Human genes 0.000 claims description 5
- 108010019236 Fucosyltransferases Proteins 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000003115 germ cell cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000013599 cloning vector Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000010324 immunological assay Methods 0.000 claims description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 230000000903 blocking effect Effects 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 102000049823 human TIGIT Human genes 0.000 description 16
- 108700017028 mouse T cell Ig and ITIM domain Proteins 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 230000002195 synergetic effect Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 239000012636 effector Substances 0.000 description 12
- 108700008625 Reporter Genes Proteins 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 11
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 238000010494 dissociation reaction Methods 0.000 description 10
- 230000005593 dissociations Effects 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000005253 yeast cell Anatomy 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000003285 pharmacodynamic effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 239000000562 conjugate Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000008228 bacteriostatic water for injection Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 229950007133 tiragolumab Drugs 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012470 diluted sample Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229960003852 atezolizumab Drugs 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 3
- 102100038077 CD226 antigen Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 3
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241001631646 Papillomaviridae Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 description 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 2
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 2
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 2
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 2
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 2
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000002100 tumorsuppressive effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- BUZOGVVQWCXXDP-VPENINKCSA-N 8-oxo-dGTP Chemical compound O=C1NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 BUZOGVVQWCXXDP-VPENINKCSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101100369640 Homo sapiens TIGIT gene Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101150065403 NECTIN2 gene Proteins 0.000 description 1
- 108060005251 Nectin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000001988 antibody-antigen conjugate Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012893 effector ligand Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical class C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003303 ruthenium Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to antibodies or antigen-binding fragments thereof that specifically bind to TIGIT and compositions containing the antibodies or antigen-binding fragments thereof.
- the present invention relates to nucleic acids encoding said antibodies or antigen-binding fragments thereof, host cells comprising them, and related uses.
- the invention relates to therapeutic and diagnostic uses of these antibodies or antigen-binding fragments thereof.
- T cell immunoglobulin and ITIM domains T cell immunoreceptor with Ig and ITIM domains, TIGIT, also known as WUCAM, Vstm3, VSIG9
- TIGIT T cell immunoreceptor with Ig and ITIM domains
- WUCAM WUCAM
- Vstm3 VSIG9
- TIGIT participates in a complex regulatory network in tumor immunity involving multiple immunosuppressive receptors (e.g., CD96/TACTILE, CD112R/PVRIG), a competitive costimulatory receptor (DNAM-1/CD226) and multiple ligands.
- CD155 PVR/NECL-5
- CD112 Nectin-2/PVRL2
- DNAM-1, TIGIT, and CD96 are expressed on T cells and NK cells and share CD155 as a ligand.
- TIGIT deficiency can delay the growth of B16F10 and MC38 subcutaneous tumors (Kurtulus S, Sakuishi K, Ngiow SF, et al.
- TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015 Nov 2 ; 125(11):4053-62.). Furthermore, when mice were inoculated with melanoma B16 cells, very few TIGIT-/- mice developed lung metastases compared with mice with normal expression of the TIGIT gene, and the overall survival of TIGIT-/- tumor-bearing mice The period was significantly prolonged (Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018 Jul; 19(7):723-732.). These results suggest that TIGIT plays a key role in tumor immunity as an immunosuppressive receptor.
- TIGIT-blocking monoclonal antibodies for therapeutic intervention to enhance the activity of T or NK cells to Play anti-tumor effect (Guillerey C, Harjunpaa H, Carrie N, et al. TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. Blood 2018, 132, 1689–1694.).
- anti-TIGIT monoclonal antibody can delay the growth of CT26 subcutaneous tumors and methylcholanthracene (MCA)-induced fibroids, and can also protect mice from experimental metastasis of 4T1 or B16 tumors (Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018Jul; 19(7):723-732.).
- TIGIT is considered to be an attractive target for tumor immunotherapy. Therefore, there is a need in the art to develop new TIGIT antibodies for use in disease treatment, especially cancer treatment.
- the inventors of the present application obtained a series of anti-TIGIT fully human antibodies, which have high binding affinity to TIGIT, can effectively block the binding of TIGIT to its ligand CD155/CD112, reduce or eliminate the transmission to Inhibitory signals of cells, administration of the antibodies of the present invention can significantly inhibit tumor growth in animal models. Based on this, the present application also provides a composition containing the antibody or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or an antigen-binding fragment thereof, a host cell containing the same, and related uses.
- the application provides an antibody or an antigen-binding fragment thereof capable of specifically binding to TIGIT, the antibody or an antigen-binding fragment thereof comprising:
- the variant has one or several amino acid substitutions, deletions or additions (eg 1, 2 or 3 amino acid substitutions, deletions or additions, eg conservative substitutions) compared to the sequence from which it is derived.
- the substitutions are conservative substitutions.
- the antibody or antigen-binding fragment thereof comprises: the 3 CDRs contained in the heavy chain variable region (VH) as set forth in SEQ ID NO:4; and/or, as set forth in SEQ ID NO: The three CDRs contained in the light chain variable region (VL) shown in 8.
- the 3 CDRs contained in the VH and/or the 3 CDRs contained in the VL are defined by the Kabat, IMGT or Chothia numbering system.
- the antibody or antigen-binding fragment thereof comprises:
- the CDR is defined by the IMGT numbering system.
- the antibody or antigen-binding fragment thereof further comprises a framework region of a human immunoglobulin.
- the antibody or antigen-binding fragment thereof comprises a framework region comprised in the amino acid sequence encoded by a human germline antibody gene. In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain framework region contained in an amino acid sequence encoded by a human heavy chain germline gene, and/or an amino acid encoded by a human light chain germline gene The light chain framework region contained in the sequence.
- the antibody or antigen-binding fragment thereof comprises: a VH comprising a sequence as shown in SEQ ID NO:4 or a variant thereof, and/or, comprising a sequence as shown in SEQ ID NO:8 VL of its variants;
- the variant has one or several amino acid substitutions, deletions or additions compared to the sequence from which it is derived (for example, 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) , or have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% , or sequences with 100% sequence identity.
- the substitutions are conservative substitutions.
- the antibody or antigen-binding fragment thereof comprises a VH as set forth in SEQ ID NO:4, and/or, a VL as set forth in SEQ ID NO:8.
- the antibody or antigen-binding fragment thereof is capable of specifically binding to human TIGIT and/or blocking the binding of human TIGIT to its ligand, for example, the binding activity and/or blocking activity is superior to tiragolumab.
- the antibody or antigen-binding fragment thereof is capable of specifically binding mouse TIGIT and/or blocking the binding of mouse TIGIT to its ligand.
- the antibody or antigen-binding fragment thereof is cross-reactive with human, cynomolgus and/or mouse TIGIT, e.g., is cross-reactive with human, cynomolgus and mouse TIGIT active.
- the application provides an antibody or an antigen-binding fragment thereof capable of specifically binding to TIGIT, the antibody or an antigen-binding fragment thereof comprising:
- the variant has one or several amino acid substitutions, deletions or additions (e.g. 1, 2 or 3 amino acid substitutions, deletions or additions, e.g. conservative substitutions) compared to the sequence from which it is derived.
- the substitutions are conservative substitutions.
- the antibody or antigen-binding fragment thereof comprises: the 3 CDRs contained in the heavy chain variable region (VH) as set forth in SEQ ID NO: 12; and/or, as set forth in SEQ ID NO: 16 shows the three CDRs contained in the light chain variable region (VL).
- the 3 CDRs contained in the VH and/or the 3 CDRs contained in the VL are defined by the Kabat, IMGT or Chothia numbering system.
- the antibody or antigen-binding fragment thereof comprises:
- the CDR is defined by the IMGT numbering system.
- the antibody or antigen-binding fragment thereof further comprises a framework region of a human immunoglobulin.
- the antibody or antigen-binding fragment thereof comprises a framework region comprised in the amino acid sequence encoded by a human germline antibody gene. In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain framework region contained in an amino acid sequence encoded by a human heavy chain germline gene, and/or an amino acid encoded by a human light chain germline gene The light chain framework region contained in the sequence.
- the antibody or antigen-binding fragment thereof comprises: a VH comprising a sequence as shown in SEQ ID NO: 12 or a variant thereof, and/or, comprising a sequence as shown in SEQ ID NO: 16 VL of its variants;
- the variant has one or several amino acid substitutions, deletions or additions compared to the sequence from which it is derived (for example, 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) , or have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% , or sequences with 100% sequence identity.
- the substitutions are conservative substitutions.
- the antibody or antigen-binding fragment thereof comprises a VH as set forth in SEQ ID NO:12, and/or, a VL as set forth in SEQ ID NO:16.
- the antibody or antigen-binding fragment thereof is capable of specifically binding to human TIGIT and/or blocking the binding of human TIGIT to its ligand, for example, the binding activity and/or blocking activity is superior to tiragolumab.
- the antibody or antigen-binding fragment thereof is cross-reactive with human and cynomolgus TIGIT.
- the antibodies or antigen-binding fragments thereof of the first and second aspects of the invention further comprise constant regions derived from human immunoglobulins.
- the heavy chain of the antibody or antigen-binding fragment thereof comprises a human immunoglobulin heavy chain constant region (CH) or a variant thereof having a or multiple amino acid substitutions, deletions or additions (for example, up to 20, up to 15, up to 10, or up to 5 amino acid substitutions, deletions or additions; for example 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions); and/or,
- CH human immunoglobulin heavy chain constant region
- the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region (CL) of a human immunoglobulin or a variant thereof having conservative substitutions of up to 20 amino acids compared to the sequence from which it is derived ( For example, conservative substitutions of up to 15, up to 10, or up to 5 amino acids; eg, conservative substitutions of 1, 2, 3, 4 or 5 amino acids).
- CL light chain constant region
- the variant of the heavy chain constant region (CH) may have a conservative substitution of one or more amino acids compared to the sequence from which it is derived. In such embodiments, the variant of the heavy chain constant region (CH) may have the same or substantially the same effector function as the wild-type sequence from which it is derived.
- variants of the heavy chain constant region may comprise one or more amino acid mutations or chemical modifications to alter one or more of the following properties of the antibodies of the invention: Fc receptor binding , antibody glycosylation, number of cysteine residues, effector cell function or complement function, etc.
- Effector function can be altered by substituting at least one amino acid residue in the constant region of the antibody with a different residue or chemically modifying, for example, altering the affinity of the antibody for an effector ligand such as FcR or complement C1q (e.g. decrease or increase).
- the Fc region of an antibody mediates several important effector functions such as ADCC, phagocytosis, CDC, etc.
- the antibody or antigen-binding fragment thereof possesses ADCC activity.
- the antibody or antigen-binding fragment thereof comprises a mutated (e.g., amino acid substitution) or chemically modified Fc region, wherein the mutated or chemically modified Fc region provides an increased ADCC activity.
- the antibody or antigen-binding fragment thereof is produced by expression in a host cell having low or no fucosylation activity, and the antibody produced has hypofucosylation or afucosylation Glycosylation, thereby increasing its ADCC activity.
- host cells may be mammalian cells lacking expression of a gene encoding a fucosyltransferase (eg FUT8), eg CHO cells.
- the heavy chain constant region is an IgG heavy chain constant region, eg, an IgGl, IgG2, IgG3 or IgG4 heavy chain constant region, eg, an IgGl heavy chain constant region.
- the antibody or antigen-binding fragment thereof is selected from IgG, such as IgG1, IgG2, IgG3 or IgG4.
- the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain constant region as set forth in SEQ ID NO: 17 or SEQ ID NO: 18.
- the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region derived from a human immunoglobulin (eg, kappa or lambda). In certain exemplary embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region set forth in SEQ ID NO: 22.
- the antigen-binding fragment is selected from the group consisting of Fab, Fab', (Fab') 2 , Fv, disulfide-linked Fv, scFv, diabody, and single domain antibody (sdAb); and /Or, the antibody is a chimeric antibody, a bispecific antibody or a multispecific antibody.
- the antibodies of the present invention can be prepared by various methods known in the art, for example, by genetic engineering and recombination techniques. For example, DNA molecules encoding the heavy and light chain genes of the antibodies of the present invention are obtained by chemical synthesis or PCR amplification. The resulting DNA molecule is inserted into an expression vector and then transfected into a host cell. Then, the transfected host cells are cultured under specific conditions, and express the antibody of the present invention.
- Antigen-binding fragments of the present invention can be obtained by hydrolyzing intact antibody molecules (see Morimoto et al., J. Biochem. Biophys. Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)) . In addition, these antigen-binding fragments can also be directly produced by recombinant host cells (reviewed in Hudson, Curr. Opin. Immunol. 11:548-557 (1999); Little et al., Immunol. Today, 21:364-370 (2000 )).
- Fab' fragments can be obtained directly from host cells; Fab' fragments can be chemically coupled to form F(ab') 2 fragments (Carter et al., Bio/Technology, 10:163-167 (1992)).
- Fv, Fab or F(ab') 2 fragments can also be directly isolated from the culture medium of recombinant host cells. Other techniques for preparing these antigen-binding fragments are well known to those of ordinary skill in the art.
- the application provides an isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof, or a heavy chain variable region and/or a light chain variable region thereof, as described above.
- the isolated nucleic acid molecule comprises a first nucleotide sequence encoding a heavy chain or a heavy chain variable region of an antibody or antigen-binding fragment thereof of the invention and a sequence encoding the antibody or antigen-binding fragment thereof.
- the isolated nucleic acid molecule of the present invention comprises a second nucleotide sequence comprising the first nucleotide sequence.
- the present application provides a vector comprising a nucleic acid molecule as described above.
- the vector is a cloning vector or an expression vector.
- the vector comprises a first nucleotide sequence encoding a heavy chain or a heavy chain variable region of an antibody of the invention or an antigen-binding fragment thereof and encoding a light chain of the antibody or an antigen-binding fragment thereof Or the second nucleotide sequence of the light chain variable region, wherein said first nucleotide sequence and said second nucleotide sequence are present on the same or different vectors.
- the vector of the present invention comprises a first vector containing the first nucleotide sequence and a vector containing the A second vector of the second nucleotide sequence.
- the present application also provides a host cell comprising the nucleic acid molecule or vector as described above.
- host cells include, but are not limited to, prokaryotic cells such as bacterial cells (such as E. coli cells), and eukaryotic cells such as fungal cells (such as yeast cells), insect cells, plant cells, and animal cells (such as mammalian cells, such as small mouse cells, human cells, etc.).
- the host cell has low or no fucosylation activity.
- the host cell may be a mammalian cell lacking expression of a gene encoding a fucosyltransferase (eg, FUT8), eg, a CHO cell.
- a fucosyltransferase eg, FUT8
- the present application provides a method for preparing the above-mentioned antibody or antigen-binding fragment thereof, which comprises culturing the above-mentioned host cell under conditions that allow expression of the antibody or antigen-binding fragment thereof, and The antibody or antigen-binding fragment thereof is recovered from cultured host cell culture.
- the host cell has low or no fucosylation activity, thereby producing a low or no fucosylation antibody to enhance the ADCC activity of the antibody produced therein.
- the host cell may be a mammalian cell lacking expression of a gene encoding a fucosyltransferase (eg, FUT8), eg, a CHO cell.
- the present application provides a pharmaceutical composition
- a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, an isolated nucleic acid molecule, a vector or a host cell as described above, and a pharmaceutically acceptable carrier and/or excipient.
- the pharmaceutical composition further comprises an additional immune checkpoint inhibitor.
- the pharmaceutical composition further comprises an anti-PD-1 antibody or an anti-PD-L1 antibody.
- the pharmaceutically acceptable carrier and/or excipient comprises a sterile injectable liquid (eg, aqueous or non-aqueous suspension or solution).
- a sterile injectable liquid eg, aqueous or non-aqueous suspension or solution.
- sterile injectable liquids are selected from the group consisting of water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (eg 0.9% (w/v) NaCl), dextrose solutions (eg, 5% dextrose), solutions containing surfactants (eg, 0.01% polysorbate 20), pH buffered solutions (eg, phosphate buffered saline), Ringer's solutions, and any combination thereof.
- WFI water for injection
- BWFI bacteriostatic water for injection
- sodium chloride solution eg 0.9% (w/v) NaCl
- dextrose solutions eg, 5% dextrose
- surfactants eg, 0.01% polysorb
- the present application provides the above-mentioned antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, vector, host cell or pharmaceutical composition for the use of the preparation of a medicament, and the medicament is used for:
- the immune cells are T cells, and/or, NK cells.
- the immune response is a T cell or NK cell mediated immune response.
- the tumor involves TIGIT-positive infiltrating T cells and/or NK cells, and/or involves TIGIT ligand (eg, CD155 and/or CD112)-positive tumor cells.
- TIGIT ligand eg, CD155 and/or CD112
- the tumor is selected from solid tumors or hematological tumors (eg, leukemia, lymphoma, myeloma).
- hematological tumors eg, leukemia, lymphoma, myeloma
- the tumor is selected from the group consisting of colorectal cancer, colon cancer, bladder cancer, breast cancer, uterine/cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, renal Cancer, head and neck cancer, lung cancer, gastric cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, tumors of the central nervous system, lymphoma, leukemia, myeloma, sarcoma, melanoma.
- the infection is selected from a viral infection, a bacterial infection, a fungal infection, and a parasitic infection.
- the subject is a mammal, such as a human, cynomolgus monkey, or mouse.
- the antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, vector, host cell, or pharmaceutical composition is used alone or in combination with another pharmaceutically active agent.
- the additional pharmaceutically active agent is an additional immune checkpoint inhibitor.
- the antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, vector, host cell or pharmaceutical composition is used in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody.
- the present application provides a method for enhancing immune response or preventing and/or treating tumor or infection in a subject, comprising: administering to a subject in need thereof an effective amount of the above-mentioned Antibodies or antigen-binding fragments thereof or pharmaceutical compositions.
- the tumor involves TIGIT-positive infiltrating T cells and/or NK cells, and/or involves TIGIT ligand (eg, CD155 and/or CD112)-positive tumor cells.
- TIGIT ligand eg, CD155 and/or CD112
- the tumor is selected from solid tumors or hematological tumors (eg, leukemia, lymphoma, myeloma).
- hematological tumors eg, leukemia, lymphoma, myeloma
- the tumor is selected from the group consisting of colorectal cancer, colon cancer, bladder cancer, breast cancer, uterine/cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, renal Cancer, head and neck cancer, lung cancer, gastric cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, tumors of the central nervous system, lymphoma, leukemia, myeloma, sarcoma, melanoma.
- the infection is selected from a viral infection, a bacterial infection, a fungal infection, and a parasitic infection.
- the subject is a mammal, such as a human.
- the antibody or antigen-binding fragment thereof or the pharmaceutical composition of the present application can be formulated into any dosage form known in the medical field, for example, tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules , elixirs, lozenges, suppositories, injections (including injections, sterile powders for injections and concentrated solutions for injections), inhalants, sprays, etc.
- the preferred dosage form depends on the intended mode of administration and therapeutic use.
- Antibodies or antigen-binding fragments thereof or pharmaceutical compositions of the invention should be sterile and stable under the conditions of manufacture and storage.
- a preferred dosage form is injection. Such injections can be sterile injectable solutions.
- sterile injectable solutions can be prepared by incorporating in an appropriate solvent the necessary dose of an antibody or antigen-binding fragment thereof of the present invention and, optionally, concomitantly incorporating other desired ingredients including, but not limited to pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof), followed by filter sterilization.
- sterile injectable solutions can be prepared as sterile lyophilized powder (eg, by vacuum drying or freeze-drying) for ease of storage and use.
- Such sterile lyophilized powders can be dispersed in suitable carriers before use, such as water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (such as 0.9% (w/v) NaCl), Dextrose solution (eg 5% glucose), surfactant containing solution (eg 0.01% polysorbate 20), pH buffered solution (eg phosphate buffered saline), Ringer's solution and any combination thereof.
- WFI water for injection
- BWFI bacteriostatic water for injection
- sodium chloride solution such as 0.9% (w/v) NaCl
- Dextrose solution eg 5% glucose
- surfactant containing solution eg 0.01% polysorbate 20
- pH buffered solution eg phosphate buffered saline
- Ringer's solution any combination thereof.
- the antibody or antigen-binding fragment thereof of the present application, or the pharmaceutical composition of the present invention can be administered by any suitable method known in the art, including but not limited to, oral, oral, sublingual, ophthalmic, topical, parenteral, Rectal, intrathecal, intracytoplasmic reticulum, inguinal, intravesical, topical (eg, powder, ointment, or drops), or nasal routes.
- the preferred route/mode of administration is parenteral (eg, intravenous or bolus injection, subcutaneous injection, intraperitoneal injection, intramuscular injection).
- an antibody or antigen-binding fragment thereof or pharmaceutical composition of the invention is administered by intravenous injection or bolus injection.
- the application provides a conjugate comprising an antibody or antigen-binding fragment thereof as described above, and a detectable label linked to the antibody or antigen-binding fragment thereof.
- the detectable label is selected from enzymes (such as horseradish peroxidase or alkaline phosphatase), chemiluminescence reagents (such as acridinium esters, luminol and its derivatives, or ruthenium derivatives), fluorescent dyes (such as fluorescein or fluorescent protein), radionuclides or biotin.
- enzymes such as horseradish peroxidase or alkaline phosphatase
- chemiluminescence reagents such as acridinium esters, luminol and its derivatives, or ruthenium derivatives
- fluorescent dyes such as fluorescein or fluorescent protein
- the present application provides a kit comprising the antibody or antigen-binding fragment thereof or the conjugate as described above.
- the kit comprises a conjugate as described above.
- the kit comprises an antibody or antigen-binding fragment thereof as described above, and a second antibody that specifically recognizes said antibody or antigen-binding fragment thereof.
- the second antibody further includes a detectable label, such as an enzyme (such as horseradish peroxidase or alkaline phosphatase), a chemiluminescent reagent (such as acridinium esters, luminol and its derivatives, or ruthenium derivatives), fluorescent dyes (such as fluorescein or fluorescent protein), radionuclides or biotin.
- an enzyme such as horseradish peroxidase or alkaline phosphatase
- a chemiluminescent reagent such as acridinium esters, luminol and its derivatives, or ruthenium derivatives
- fluorescent dyes such as fluorescein or fluorescent protein
- the present application provides a method for detecting the presence or level of TIGIT in a sample comprising using an antibody or antigen-binding fragment thereof as described above or a conjugate as described above.
- the methods are used for therapeutic purposes, diagnostic purposes, or non-therapeutic non-diagnostic purposes.
- the method is an immunological assay, such as a western blot, an enzyme immunoassay (eg, ELISA), a chemiluminescent immunoassay, a fluorescent immunoassay, or a radioimmunoassay.
- the method comprises using a conjugate as described above.
- the method comprises the use of an antibody or antigen-binding fragment thereof as described above, and the method further comprises the use of an antibody carrying a detectable label (e.g., an enzyme such as horseradish peroxidase or alkaline phosphate enzymes), chemiluminescent reagents (such as acridinium esters, luminol and its derivatives, or ruthenium derivatives), fluorescent dyes (such as fluorescein or fluorescent protein), radionuclides or biotin) secondary antibodies to detect the antibody or antigen-binding fragment thereof.
- a detectable label e.g., an enzyme such as horseradish peroxidase or alkaline phosphate enzymes
- chemiluminescent reagents such as acridinium esters, luminol and its derivatives, or ruthenium derivatives
- fluorescent dyes such as fluorescein or fluorescent protein
- the method comprises: (1) contacting the sample with an antibody of the invention or an antigen-binding fragment thereof; (2) detecting the formation of an antigen-antibody immune complex or detecting the immune complex amount.
- the formation of such immune complexes indicates the presence of TIGIT or cells expressing TIGIT.
- the present application also provides the use of the above-mentioned antibody or its antigen-binding fragment or the above-mentioned conjugate in the preparation of a detection reagent, and the kit is used to detect the presence of TIGIT in a sample or its level.
- the detection reagent detects the presence or level of TIGIT in a sample by a method as described above.
- the sample is a sample of cells (eg, immune cells) from a subject (eg, a mammal, preferably a human, cynomolgus monkey or mouse).
- a subject eg, a mammal, preferably a human, cynomolgus monkey or mouse.
- antibody refers to an immunoglobulin molecule, usually composed of two pairs of polypeptide chains, each pair having one light chain (LC) and one heavy chain (HC).
- Antibody light chains can be classified as kappa (kappa) and lambda (lambda) light chains.
- Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
- the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also comprising a "D" region of about 3 or more amino acids.
- Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH).
- the heavy chain constant region consists of 3 domains (CH1, CH2 and CH3).
- Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL).
- the light chain constant region consists of one domain, CL.
- the constant domains are not directly involved in antibody-antigen binding, but exhibit a variety of effector functions, such as mediating immunoglobulin interactions with host tissues or factors, including various cells of the immune system (e.g., effector cells) and classical complement Binding of the first component (C1q) of the system.
- VH and VL regions can also be subdivided into regions of high variability called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs).
- CDRs complementarity determining regions
- FRs framework regions
- Each VH and VL consists of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4, from amino-terminus to carboxy-terminus.
- the variable regions (VH and VL) of each heavy chain/light chain pair form the antigen binding site, respectively.
- the allocation of amino acids in each region or domain can follow Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987and 1991)), or Chothia & Lesk (1987) J.Mol.Biol.196:901- 917; Definition by Chothia et al. (1989) Nature 342:878-883.
- CDR complementarity determining region
- the variable regions of the heavy and light chains each contain three CDRs, designated CDR1, CDR2 and CDR3.
- CDR1, CDR2 and CDR3 The precise boundaries of these CDRs can be defined according to various numbering systems known in the art, such as the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al.
- the CDRs contained in the antibody of the present invention or an antigen-binding fragment thereof can be determined according to various numbering systems known in the art.
- antibodies of the invention or antigen-binding fragments thereof contain CDRs preferably identified by the Kabat, Chothia or IMGT numbering system.
- antibodies of the invention or antigen-binding fragments thereof contain CDRs preferably identified by the IMGT numbering system.
- framework region or "FR” residues refers to those amino acid residues in an antibody variable region other than the CDR residues as defined above.
- antibody is not limited to any particular method of producing antibodies. For example, it includes recombinant antibodies, monoclonal antibodies and polyclonal antibodies. Antibodies can be of different isotypes, eg, IgG (eg, IgGl, IgG2, IgG3, or IgG4 subtype), IgAl, IgA2, IgD, IgE, or IgM antibodies.
- IgG eg, IgGl, IgG2, IgG3, or IgG4 subtype
- IgAl IgA2, IgD, IgE, or IgM antibodies.
- the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/or competes with the full-length antibody for Specific binding to an antigen, which is also referred to as an "antigen-binding moiety".
- an antigen-binding moiety See generally, Fundamental Immunology, Ch.7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Can be obtained by recombinant DNA techniques. or by enzymatic or chemical cleavage of intact antibodies to generate antigen-binding fragments of antibodies.
- Non-limiting examples of antigen-binding fragments include Fab, Fab', F(ab') 2 , Fd, Fv, complementarity determining region (CDR) fragments, scFv, diabody, single domain antibody, chimeric antibody, linear antibody, nanobody (technology from Domantis), probody, and polypeptides comprising sufficient At least a portion of an antibody of antigen binding capacity.
- Engineered antibody variants are reviewed in Holliger et al., 2005; Nat Biotechnol, 23:1126-1136.
- full-length antibody means an antibody consisting of two “full-length heavy chains” and two “full-length light chains”.
- “full-length heavy chain” refers to such a polypeptide chain, which consists of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain The CH2 domain of the constant region and the CH3 domain of the constant region of the heavy chain; and, when the full-length antibody is of the IgE isotype, optionally further includes the CH4 domain of the constant region of the heavy chain.
- a "full-length heavy chain” is a polypeptide chain consisting of VH, CH1, HR, CH2 and CH3 in the N-terminal to C-terminal direction.
- a "full-length light chain” is a polypeptide chain consisting, in the N-terminal to C-terminal direction, of a light chain variable region (VL) and a light chain constant region (CL).
- VL light chain variable region
- CL light chain constant region
- the two pairs of full-length antibody chains are linked together by a disulfide bond between CL and CH1 and between the HRs of the two full-length heavy chains.
- the full-length antibody of the present invention can be from a single species, such as human; it can also be a chimeric antibody or a humanized antibody.
- the full-length antibody of the present invention comprises two antigen-binding sites respectively formed by VH and VL pairs, and these two antigen-binding sites specifically recognize/bind to the same antigen.
- the term “Fd” means an antibody fragment consisting of VH and CH1 domains
- the term “dAb fragment” means an antibody fragment consisting of a VH domain (Ward et al., Nature 341:544 546( 1989))
- the term “Fab fragment” means an antibody fragment consisting of VL, VH, CL and CH1 domains
- the term “F(ab') 2 fragment” means a fragment comprising two An antibody fragment of a Fab fragment
- the term “Fab'fragment” means the fragment obtained after reduction of the disulfide bond linking the two heavy chain fragments in the F(ab') 2 fragment, consisting of an intact light chain and the Fd of the heavy chain Fragment (consisting of VH and CH1 domains).
- the term "Fv" means an antibody fragment consisting of the VL and VH domains of a single arm of an antibody.
- the Fv fragment is generally considered to be the smallest antibody fragment capable of forming a complete antigen-binding site. It is generally believed that the six CDRs confer antigen-binding specificity to an antibody. However, even a variable region (such as the Fd fragment, which contains only three CDRs specific for an antigen) is able to recognize and bind antigen, although perhaps with a lower affinity than the full binding site.
- Fc means that the second and third constant regions of the first heavy chain of an antibody are combined with the second and third constant regions of the second heavy chain via disulfide bonds.
- Antibody fragments The Fc fragment of an antibody has a variety of different functions, but is not involved in antigen binding.
- scFv refers to a single polypeptide chain comprising VL and VH domains, wherein the VL and VH are linked by a linker (see, e.g., Bird et al., Science 242:423 -426 (1988); Huston et al, Proc. New York, pp. 269-315 (1994)).
- linker see, e.g., Bird et al., Science 242:423 -426 (1988); Huston et al, Proc. New York, pp. 269-315 (1994)).
- Such scFv molecules may have the general structure: NH2 -VL-linker-VH-COOH or NH2 -VH-linker-VL-COOH.
- Suitable prior art linkers consist of the repeated GGGGS amino acid sequence or variants thereof.
- a linker having the amino acid sequence (GGGGS) 4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448).
- Other linkers useful in the present invention are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur.J. Immunol.31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, described by Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001) Cancer Immunol.
- scFv can form di-scFv, which refers to two or more single scFv connected in series to form an antibody.
- scFv can form (scFv) 2 , which refers to the parallel connection of two or more single scFv to form an antibody.
- the term "diabody” means that its VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow pairing between the two domains of the same chain, This forces the domain to pair with the complementary domain of another chain and creates two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak R.J. et al., Structure 2:1121-1123 (1994)).
- single-domain antibody has the meaning commonly understood by those skilled in the art, which refers to a single monomer variable antibody domain (such as a single heavy chain variable antibody domain) region) that retains the ability to specifically bind the same antigen to which the full-length antibody binds.
- Single domain antibodies are also called nanobodies.
- Each of the above antibody fragments maintains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/or competes with the full-length antibody for specific binding to the antigen.
- Antigen-binding fragments of antibodies can be obtained from a given antibody (e.g., an antibody provided herein) using conventional techniques known to those skilled in the art (e.g., recombinant DNA techniques or enzymatic or chemical cleavage methods) ), and antigen-binding fragments of antibodies are screened for specificity in the same manner as for whole antibodies.
- antibody includes not only whole antibodies but also antigen-binding fragments of antibodies.
- the term "Chimeric antibody” refers to an antibody whose light chain and/or heavy chain are partly derived from an antibody (which may be derived from a particular species or belong to a certain a specific antibody class or subclass), and the other part of the light chain or/and heavy chain is derived from another antibody (which may be derived from the same or different species or belong to the same or different antibody class or subclass), but regardless However, it still retains the binding activity to the target antigen (U.S.P 4,816,567 to Cabilly et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851 6855 (1984)).
- the term “chimeric antibody” may include antibodies in which the antibody's heavy and light chain variable regions are derived from a first antibody and the antibody's heavy and light chain constant regions are derived from a second antibody.
- the term "identity" is used to refer to the match of sequences between two polypeptides or between two nucleic acids.
- the sequences are aligned for optimal comparison purposes (for example, gaps may be introduced in a first amino acid sequence or nucleic acid sequence to best align with a second amino acid or nucleic acid sequence).
- Jiabi pair The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
- the determination of percent identity between two sequences can also be accomplished using a mathematical algorithm.
- a non-limiting example of a mathematical algorithm for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Modified from .Acad.Sci.U.S.A. 90:5873-5877. Such an algorithm was incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215:403.
- variant in the context of polypeptides (including polypeptides), also refers to a polypeptide or peptide comprising an amino acid sequence that has been altered by introducing amino acid residue substitutions, deletions or additions. In certain instances, the term “variant” also refers to a polypeptide or peptide that has been modified (ie, by covalently linking molecules of any type to the polypeptide or peptide).
- polypeptides may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, Attachment to cellular ligands or other proteins, etc.
- Derivative polypeptides or peptides can be produced by chemical modification using techniques known to those skilled in the art, including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, and the like.
- a variant has a similar, identical or improved function to the polypeptide or peptide from which it is derived.
- the term "specific binding” refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and its antigen.
- the strength or affinity of a specific binding interaction can be expressed in terms of the equilibrium dissociation constant ( KD ) for that interaction.
- KD refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between an antibody and an antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding, and the higher the affinity between the antibody and the antigen.
- the specific binding properties between two molecules can be determined using methods well known in the art.
- One method involves measuring the rate of antigen binding site/antigen complex formation and dissociation.
- Both the "association rate constant” (ka or kon) and the “dissociation rate constant” (kdis or koff) can be calculated from the concentration and actual rates of association and dissociation (see Malmqvist M, Nature, 1993, 361 :186-187).
- the ratio kdis/kon is equal to the dissociation constant KD (see Davies et al., Annual Rev Biochem, 1990; 59:439-473).
- KD , kon and kdis values can be measured by any effective method.
- dissociation constants can be measured in Biacore using surface plasmon resonance (SPR).
- bioluminescent interferometry or Kinexa can be used to measure dissociation constants.
- a detectable label according to the invention can be any substance detectable by fluorescent, spectroscopic, photochemical, biochemical, immunological, electrical, optical or chemical means.
- labels are well known in the art, examples of which include, but are not limited to, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, urease, glucose oxidase, etc.), radionuclide Chlorin (for example, 3 H, 125 I, 35 S, 14 C or 32 P), fluorescent dyes (for example, fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC) , phycoerythrin (PE), Texas Red, rhodamine, quantum dots or cyanine dye derivatives (such as Cy7, Alexa750)), luminescent substances (such as chemiluminescent substances, such as acridinium ester
- vector refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
- the vector is called an expression vector.
- a vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell.
- Vectors are well known to those skilled in the art, including but not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC) ; Phage such as lambda phage or M13 phage and animal viruses.
- artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC)
- Phage such as lambda phage or M13 phage and animal viruses.
- Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses, papillomaviruses, Polyoma vacuolar virus (eg SV40).
- a vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes.
- the vector may also contain an origin of replication.
- the term "host cell” refers to cells that can be used to introduce vectors, including, but not limited to, prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, Insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
- prokaryotic cells such as Escherichia coli or Bacillus subtilis
- fungal cells such as yeast cells or Aspergillus
- Insect cells such as S2 Drosophila cells or Sf9
- animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
- conservative substitution means an amino acid substitution that does not adversely affect or alter the expected properties of the protein/polypeptide comprising the amino acid sequence.
- conservative substitutions can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis.
- Conservative amino acid substitutions include substitutions for amino acid residues with amino acid residues that have similar side chains, e.g., are physically or functionally similar (e.g., have similar size, shape, charge, chemical properties, including Substitution of residues with the ability to form covalent or hydrogen bonds, etc.). Families of amino acid residues having similar side chains have been defined in the art.
- These families include those with basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine) , asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (such as alanine, valine, leucine, isoleucine amino acid, proline, phenylalanine, methionine), beta branched side chains (e.g. threonine, valine, isoleucine) and aromatic side chains (e.g.
- basic side chains e.g., lysine, arginine, and histidine
- acidic side chains e.g., aspartic acid, glutamic acid
- uncharged polar side chains e.g., glycine
- non-polar side chains such as
- the term "pharmaceutically acceptable carrier and/or excipient” refers to a carrier and/or excipient compatible with the subject and the active ingredient pharmacologically and/or physiologically, These are well known in the art (see e.g. Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and include, but are not limited to: pH adjusters, surfactants, adjuvants, ionic strength enhancers agents, diluents, agents to maintain osmotic pressure, agents to delay absorption, preservatives.
- pH adjusting agents include, but are not limited to, phosphate buffers.
- Surfactants include but are not limited to cationic, anionic or nonionic surfactants such as Tween-80.
- Ionic strength enhancers include, but are not limited to, sodium chloride.
- Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like.
- Agents to maintain osmotic pressure include, but are not limited to, sugars, NaCl, and the like.
- Agents that delay absorption include, but are not limited to, monostearates and gelatin.
- Diluents include, but are not limited to, water, aqueous buffers (eg, buffered saline), alcohols and polyols (eg, glycerol), and the like.
- Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, and the like.
- Stabilizer has the meaning generally understood by those skilled in the art, and it can stabilize the desired activity of the active ingredient in the medicine, including but not limited to sodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose , lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dry whey, albumin or casein) or their degradation products (such as lactalbumin hydrolyzate), etc.
- the pharmaceutically acceptable carrier or excipient comprises a sterile injectable liquid (eg, aqueous or non-aqueous suspension or solution).
- such sterile injectable liquids are selected from the group consisting of water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (eg 0.9% (w/v) NaCl), dextrose solutions (eg, 5% dextrose), solutions containing surfactants (eg, 0.01% polysorbate 20), pH buffered solutions (eg, phosphate buffered saline), Ringer's solutions, and any combination thereof.
- WFI water for injection
- BWFI bacteriostatic water for injection
- sodium chloride solution eg 0.9% (w/v) NaCl
- dextrose solutions eg, 5% dextrose
- solutions containing surfactants eg, 0.01% polysorbate 20
- pH buffered solutions eg, phosphate buffered saline
- Ringer's solutions e.g, Ringer's solutions, and any combination thereof.
- prevention refers to methods performed to prevent or delay the occurrence of a disease or disorder or symptom in a subject.
- treatment refers to a method performed to obtain a beneficial or desired clinical result.
- a beneficial or desired clinical outcome includes, but is not limited to, relief of symptoms, reduction of the extent of the disease, stabilization (i.e., no longer worsening) of the disease state, delay or slowing of the progression of the disease, amelioration or palliation of the disease status, and relief of symptoms (whether partial or total), whether detectable or undetectable.
- treating can also refer to prolonging survival as compared to expected survival if not receiving treatment.
- the term "subject” refers to mammals, such as humans, cynomolgus monkeys, mice.
- the subject e.g., human, cynomolgus monkey, mouse
- has a TIGIT-associated disease e.g., involving TIGIT-positive infiltrating T cells and/or NK cells, and/or Tumors involving tumor cells positive for TIGIT ligands (eg, CD155 and/or CD112), or, at risk of having the above diseases.
- an effective amount refers to an amount sufficient to achieve, or at least partially achieve, the desired effect.
- an effective amount for preventing a disease for example, involving TIGIT positive infiltrating T cells and/or NK cells, and/or involving TIGIT ligand (such as CD155 and/or CD112) positive tumor cells
- an effective amount for treating the disease refers to an amount sufficient to cure or at least partially prevent the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is well within the capability of those skilled in the art.
- amounts effective for therapeutic use will depend on the severity of the disease to be treated, the general state of the patient's own immune system, the general condition of the patient such as age, weight and sex, the mode of administration of the drug, and other treatments administered concomitantly etc.
- the present invention provides a fully human antibody against TIGIT, which has a high binding affinity to TIGIT, can effectively block the binding of TIGIT to its ligand CD155/CD112, reduce or eliminate the inhibitory signal transmitted to cells, and can be administered in animal models
- the antibodies of the present invention can significantly inhibit tumor growth. Therefore, the antibodies of the present invention can be used for various purposes, including but not limited to enhancing immune response, inhibiting tumor growth, anti-infection and detecting TIGIT protein.
- the fully human antibodies of the present invention can be safely administered to human subjects without eliciting immunogenic responses. Therefore, the antibodies of the present invention have great clinical value.
- Fig. 1 shows the binding activity of the anti-TIGIT antibody of the present invention to human TIGIT overexpressed on CHO cells.
- Figure 2 shows the binding activity of the anti-TIGIT antibody of the present invention to cynomolgus monkey TIGIT overexpressed on CHO cells.
- Fig. 3 shows the binding activity of the anti-TIGIT antibody of the present invention to mouse TIGIT overexpressed on CHO cells.
- Figure 4 shows the blocking activity of anti-TIGIT antibodies of the present invention to block the binding of human CD155 to human TIGIT overexpressed on CHO cells.
- Figure 5 shows the blocking activity of the anti-TIGIT antibody of the present invention to block the binding of mouse CD155 to mouse TIGIT overexpressed on CHO cells.
- Fig. 6 shows the binding activity of the anti-TIGIT antibody of the present invention to TIGIT on activated human primary T cells.
- Fig. 7 shows the blocking activity of the anti-TIGIT antibody monoclonal antibody molecules of the present invention to block the TIGIT/CD155 signaling pathway.
- Figures 8A-8B show that the anti-TIGIT antibody of the present invention cooperates with anti-PD-L1/PD-1 molecules to block TIGIT/CD155/CD112, the blocking activity of PD-L1/PD-1 signaling pathway.
- Figures 9A-C show the in vitro ADCC activity of anti-TIGIT antibodies of the invention.
- 10A-B show the pharmacodynamic study of the anti-TIGIT antibody of the present invention in the wild-type mouse CT-26 tumor model.
- Figure 11 shows the synergistic pharmacodynamic study of the anti-TIGIT antibody of the present invention and the anti-PD-L1 antibody in the wild-type mouse CT-26 tumor model.
- Figure 12A-B shows the synergistic pharmacodynamic study of the anti-TIGIT antibody of the present invention and the anti-PD-L1 antibody in the huTIGIT KI mouse CT-26 tumor model.
- Figure 13 shows the synergistic pharmacodynamic study of the anti-TIGIT antibody of the present invention and the anti-PD-L1 antibody in the B-NDG mouse model inoculated with A375 and human PBMC.
- Figures 14A-B show half-life studies of anti-TIGIT antibodies of the invention in mice.
- the molecular biology experiment methods and immunoassay methods used in the present invention are basically with reference to J.Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and F.M.Ausubel et al., Compiled Molecular Biology Experimental Guide, 3rd Edition, John Wiley & Sons, Inc., 1995 by the method described; restriction endonucleases were used in accordance with the conditions recommended by the product manufacturer.
- restriction endonucleases were used in accordance with the conditions recommended by the product manufacturer.
- yeast antibody display library (Adimab) Based on the yeast antibody display library (Adimab), amplification was performed according to existing methods (see patent applications WO2009036379, WO2010105256 and WO2012009568), wherein the diversity of each library reached 1 ⁇ 10 9 . Briefly, the first two rounds of screening were performed using Miltenyi's MACS system for magnetic bead cell sorting. First, incubate the yeast cells in the library ( ⁇ 1 ⁇ 10 10 cells/library) in FACS washing buffer (phosphate buffered saline containing 0.1% BSA) for 15 minutes at room temperature, and the buffer contains 100 nM biotin-labeled human TIGIT antigen (purchased from Acro, Cat. No.: TIT-H5254).
- FACS washing buffer phosphate buffered saline containing 0.1% BSA
- the culture medium was discarded, and after the cells were washed twice with FACS washing buffer, the cells were mixed with LC-FITC (FITC-labeled anti-human immunoglobulin kappa light chain antibody, purchased from Southern Biotech) (1:100 dilution), and Mix with SA-633 (Streptavidin-633, purchased from Molecular Probes) (1:500 dilution) or SA-PE (Streptavidin-PE, purchased from Sigma) (1:50 dilution), 40 Incubate for 15 minutes at °C. Elute twice with pre-cooled FACS wash buffer and resuspend in 0.4 mL of buffer, transfer the cells to a separation tube with filter. Cells were sorted using FACS ARIA (BD Biosciences).
- yeast cells obtained by screening were shaken and induced at 30°C for 48 hours to secrete and express the target anti-TIGIT antibody (full-length IgG). After the induction, yeast cells were removed by centrifugation at 1300 rpm for 10 minutes, and the supernatant was harvested. Purify the anti-TIGIT antibody in the supernatant using Protein A, elute with pH 2.0 acetic acid solution, and harvest the anti-TIGIT antibody.
- the CDRH3 gene of the parent molecule was constructed into a 1 ⁇ 10 8 diversity CDRH1/CDRH2 gene library, and three rounds of screening were performed on it.
- the MACS method was used in the first round, and the FACS method was used in the second and third rounds to pressurize the affinity of the antibody-antigen conjugate and screen out high-affinity antibodies.
- the yeast cells obtained by screening and expressing anti-TIGIT antibody were shaken and cultured at 30°C for 48 hours to produce TIGIT antibody. After the induced expression was completed, the yeast cells were removed by centrifugation at 1300 rpm for 10 minutes, and the supernatant was harvested.
- the anti-TIGIT antibody in the supernatant was purified using Protein A, eluted with pH 2.0 acetic acid solution, and the anti-TIGIT antibody was harvested.
- the corresponding Fab fragments were obtained using papain and purified with KappaSelect (GE Life Medical Group).
- the method is to introduce mutations into the heavy chain region by conventional mismatch PCR method.
- the base mismatch probability was increased to about 0.01 bp.
- the product obtained by mismatch PCR was constructed into a vector containing the heavy chain constant region by homologous recombination.
- a secondary library with a capacity of 1 ⁇ 107 was obtained under screening pressures including TIGIT antigen titer, competition with unlabeled antigen, and competition with parental antibody, three rounds of screening by FACS method, yeast expression Corresponding antibody.
- the CDRL3 diversity gene was constructed into the CDRL1/CDRL2 gene library through homologous recombination to obtain a secondary library with a storage capacity of 1 ⁇ 10 7 , which was screened by one round of MACS and two rounds of FACS, and the yeast expressed the corresponding antibody.
- antibody molecules ADI-55796 and ADI-55812 after affinity maturation were obtained.
- the sequences and sequence numbers of ADI-55796 and ADI-55812 are shown in Table 1, wherein the CDRs are determined by the IMGT numbering system.
- Tiragolumab is an anti-human TIGIT antibody from Genentech expressed by HEK293 cells, and its light and heavy chain variable region sequences are consistent with INN list 177NO 1918185-84-8 .
- Transient expression and purification via the HEK293 expression system the specific operation is as follows: use the chemical transfection method to transfer the pcDNA3.1 vector carrying the antibody heavy chain and light chain into HEK293 cells, and culture at 37°C and 8% CO 2 7 days. The cell fluid was collected and centrifuged at 13000rpm for 20 minutes. Take the supernatant, Protein A purification supernatant, SEC to detect the purity of the antibody, while controlling the endotoxin content. Finally, antibodies ADI-55796-G1, ADI-55812-G1, ADI-55796-G1LALA, ADI-55812-G1LALA were obtained.
- the antibodies ADI-55796-G1, ADI-55812-G1, ADI-55796-G1LALA, and ADI-55812-G1LALA obtained in Example 1 were combined with human, cynomolgus monkey, and mouse TIGIT using biofilm layer optical interference technology (ForteBio).
- the binding dissociation constant (K D ) Fortebio affinity was determined according to existing methods (Este, P et al. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. Mabs, 2013.5 (2): p.270-8), the human, cynomolgus monkey
- the amino acid sequences of the extracellular segment of TIGIT and mouse are respectively shown in SEQ ID NO: 19-21.
- the sensor is equilibrated offline for 20 minutes in the assay buffer, and then detected online for 120s to establish a baseline, and load the intact TIGIT antibody to the AHQ sensor to a thickness 1nm for affinity detection.
- Antibody-loaded sensors were plateaued in 100 nM TIGIT-his antigen, then the sensors were transferred to assay buffer for at least 2 minutes for off-rate measurements.
- Kinetic analysis was performed using a 1:1 binding model.
- Anti-TIGIT clones ADI-55796 and ADI-55812 have high binding activity to human TIGIT and cynomolgus monkey TIGIT.
- ADI-55796 also has cross-binding activity to mouse TIGIT.
- Example 3 Binding activity and blocking activity of anti-TIGIT antibodies to overexpressed human/cynomolgus monkey/mouse TIGIT CHO cells
- the pCHO1.0 vector purchased from Invitrogen
- human TIGIT human TIGIT
- cynomolgus TIGIT mouse TIGIT cDNA cloned into MCS was transfected to produce CHO-S cells (CHO-huTIGIT cells) overexpressing human TIGIT.
- CHO-S cells overexpressing cynomolgus TIGIT
- CHO-muTIGIT cells CHO-muTIGIT cells
- the expanded cultured CHO-huTIGIT cells were adjusted to a cell density of 2 ⁇ 10 6 cells/mL, 100 ⁇ L/well was added to a 96-well flow plate, and centrifuged for later use. Dilute the purified monoclonal antibody with PBS, starting at 400nM and diluting 3 times for a total of 12 points. Add 60 ⁇ L/well of the diluted sample into the above-mentioned 96-well flow plate with cells, and incubate at 4°C for 30 minutes.
- Example 4 Anti-TIGIT antibody binds to TIGIT on the surface of primary T cells
- the binding activity of the invented anti-TIGIT antibody to TIGIT on the surface of activated T cells was detected based on the flow cytometry detection method.
- human PBMCs were sorted according to the protocol provided by STEMCELL (stemcell, catalog number: #17951C) to obtain human total T cells.
- Use X-VIVO15 medium (purchased from lonza, product number: 04-418Q) to adjust the concentration of T cells to 1.0 ⁇ 10 6 cells/mL, add 1 ⁇ L IL-2 stock solution (1 million IU), and simultaneously 1:1 (bead- to-cell) were added to CD3/CD28 Dynabeads (purchased from gibco, product number: 11132D), and cultured in a 5% CO 2 incubator at 37° C. for 48 hours.
- the activated T cells were adjusted to a suitable cell density and added to a 96-well flow plate.
- the samples to be tested were added in a gradient dilution and incubated at 4°C for 30 minutes. Wash twice with PBS, add corresponding fluorescent secondary antibody diluted to an appropriate concentration, incubate at 4°C for 30 minutes, wash twice with PBS. Add PBS to resuspend cells, detect on CytoFlex flow cytometer and calculate corresponding MFI.
- Figure 6 the results show that the anti-TIGIT antibodies ADI-55796-G1, ADI-55796-G1LALA, ADI-55812-G1, ADI-55812-G1LALA of the present invention can bind TIGIT molecules on the surface of activated T cells, and the binding activity Outperformed the reference molecule Tiragolumab.
- Embodiment 5 Luciferase reporter gene system detects anti-TIGIT antibody activity
- a luciferase reporter gene system was constructed in this example.
- cells were transfected with lentivirus to construct CHO-K1 overexpressing human CD155 and OKT-3 scFv Cell line (CHO-K1-CD155), a Jurkat cell line (Jurkat-TIGIT-luc) overexpressing human TIGIT and NF-AT luciferase reporter genes was constructed, and this reporter gene system was used to carry out related experiments.
- the CHO-K1-CD155 functional cells were obtained by digestion, the cell density was adjusted, 100 ⁇ L/well was added to a 96-well white bottom plate, and the adherent culture was carried out overnight. On the second day, a Jurkat-TIGIT-luc effector cell suspension was prepared, and the test sample was serially diluted with a reaction medium (RPMI1640+10% FBS).
- Example 6 Detection of synergistic effect of anti-TIGIT antibody and anti-PD-L1/PD-1 antibody by luciferase reporter gene system
- this example constructed the following luciferase reporter gene system, briefly described as, on the basis of Example 5, slowly Virus infected CHO-K1-CD155 to overexpress CD122 and PD-L1 to obtain CHO-K1-CD155-CD112-PD-L1 functional cells, and lentivirus infected Jurkat-TIGIT-luc to overexpress PD-1 to obtain Jurkat-TIGIT- PD-1-luc effector cell suspension, and then use this reporter gene system to carry out related experiments.
- CHO-K1-CD155-CD112-PD-L1 functional cells were obtained by digestion, the cell density was adjusted, 100 ⁇ L/well was added to a 96-well white bottom plate, and adherent culture was carried out overnight. The next day, a Jurkat-TIGIT-PD-1-luc effector cell suspension was prepared, and the samples to be tested (the anti-PD-1/PD-L1 antibodies used were Atezolizumab and Pembrolizumab) were serially diluted with the reaction medium.
- Example 7 Detection of ADCC activity of anti-TIGIT antibody in vitro
- the in vitro ADCC activity of the anti-TIGIT antibody of the present invention was detected.
- Jurkat-NFAT-Luciferase-CD16ADCC effector cells purchased from Promega
- the cells were resuspended to 4 ⁇ 10 6 cells/mL in 1640 medium containing 10% low IgG FBS.
- the CT-26 cell tumor-bearing mouse model was established by subcutaneous inoculation.
- the average tumor volume grew to 100-200mm, they were divided into groups , and treated with different doses of the anti-TIGIT antibody of the present invention by intraperitoneal injection.
- the tumor volume and body weight of the mice in the group were monitored at a frequency of 2-3 days/time for 2 to 3 weeks, and the dosage and method of administration were shown in Table 4-5.
- the results are shown in Figures 10A-B, and the results show that the anti-TIGIT antibody ADI-55796-G1 of the present invention can significantly inhibit the growth of tumors in mice in a dose-dependent manner.
- Example 9 Study on the synergistic pharmacodynamics of anti-TIGIT antibody and anti-PD-L1 antibody in wild-type Balb/c mice
- the CT-26 cell tumor-bearing mouse model was first established by subcutaneous inoculation, and grouped when the average tumor volume grew to 100-200 mm 3 , and the anti-TIGIT antibody and/or anti-PD-L1 antibody of the present invention were administered intraperitoneally.
- (Atezolizumab) treatment monitor the changes in tumor volume and body weight of the mice in each group, the monitoring frequency is 2-3 days/time, continuous monitoring for 2 to 3 weeks, the dosage and method of administration are shown in Table 6. The results are shown in Figure 11.
- the anti-TIGIT antibody ADI-55796-G1 of the present invention combined with the anti-PD-L1 antibody Atezolizumab had significantly better tumor inhibitory activity than the corresponding two mAb treatment groups. It is suggested that the anti-TIGIT antibody ADI-55796-G1 of the present invention can exert synergistic anti-tumor activity with the anti-PD-L1 antibody Atezolizumab in the wild-type mouse CT-26 model.
- Example 10 Study on the synergistic pharmacodynamics of anti-TIGIT antibody and anti-PD-L1 antibody in huTIGIT KI mice
- CT-26 tumor cells were transplanted into human TIGIT transgenic mice (huTIGIT KI mice) to determine the synergistic anti-tumor effect of the TIGIT antibody of the present invention and the anti-PD-L1 antibody.
- the CT-26 tumor-bearing mouse model was first established by subcutaneous inoculation. When the average tumor volume grew to 80-120 mm 3 , they were divided into groups, treated with different antibodies and different doses by intraperitoneal injection, and the tumors of mice in each group were monitored. Volume and body weight changes, the monitoring frequency is 2-3 days/time, and continuous monitoring is 2 to 3 weeks.
- the dosage and method of administration are shown in Table 7-8.
- the results are shown in Figure 12A-B, the results show that the anti-TIGIT antibodies ADI-55796-G1, ADI-55796-G1LALA, and ADI-55812-G1 of the present invention are all effective in human TIGIT transgenic mice transplanted with CT-26 tumor cells. Synergistic antitumor activity was observed with the anti-PD-L1 antibody atezolizuamb.
- Table 7 Dosing regimen of anti-TIGIT antibody and anti-PD-L1 antibody (corresponding to Figure 12A)
- Table 8 Dosing regimen of anti-TIGIT antibody and anti-PD-L1 antibody (corresponding to Figure 12B)
- Example 11 Study on synergistic pharmacodynamics of anti-TIGIT antibody and anti-PD-L1 antibody in B-NDG mice inoculated with A375 and human PBMC in vivo
- B-NDG mice were inoculated with A375 (purchased from Addexbio, article number: C0020004) and human PBMC cells (Shanghai Miaoshun, A10S033014/PB100C) to determine the synergistic anti-PD-L1 antibody of the present invention. tumor effect.
- A375 and human PBMC tumor-bearing mouse models were established by subcutaneous mixed inoculation. When the average tumor volume grew to about 200 mm 3 , they were divided into groups, treated with different antibodies and different doses by intraperitoneal injection, and the mice in each group were monitored. For changes in tumor volume and body weight, the monitoring frequency was 2-3 days/time, and the monitoring was continuous for 2 to 3 weeks.
- the dosage and method of administration are shown in Table 9.
- Table 9 Synergistic administration regimen of anti-TIGIT antibody and anti-PD-L1 antibody A375 model
- mice The half-life of the anti-TIGIT antibody of the present invention in mice was detected by a single tail vein injection method.
- Balb/c mice were used in the experiment, half male and half male, 12/12 hours light/dark adjustment, temperature 24 ⁇ 2°C, humidity 40-70%, free access to water and diet.
- Balb/c mice were injected with a single monoclonal antibody molecule into the tail vein, and the injection dose was 10 mg/kg.
- Blood collection time point 5 minutes, 0.5 hours, 2 hours, 6 hours, 24 hours, 48 hours, 96 hours, 168 hours, 336 hours, and 504 hours after administration, blood was collected from the mouse orbit.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (17)
- 能够特异性结合TIGIT的抗体或其抗原结合片段,所述抗体或其抗原结合片段包含:(a)如SEQ ID NO:4所示的重链可变区(VH)中含有的VH CDR1或其变体、VH CDR2或其变体以及VH CDR3或其变体;和/或,如SEQ ID NO:8所示的轻链可变区(VL)中含有的VL CDR1或其变体、VL CDR2或其变体以及VL CDR3或其变体;或,(b)如SEQ ID NO:12所示的重链可变区(VH)中含有的VH CDR1或其变体、VH CDR2或其变体以及VH CDR3或其变体;和/或,如SEQ ID NO:16所示的轻链可变区(VL)中含有的VL CDR1或其变体、VL CDR2或其变体以及VL CDR3或其变体;其中,所述变体与其所源自的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个,2个或3个氨基酸的置换、缺失或添加,例如保守置换);优选地,所述的置换是保守置换;优选地,所述抗体或其抗原结合片段包含:(a)如SEQ ID NO:4所示的重链可变区(VH)中含有的3个CDR;和/或,如SEQ ID NO:8所示的轻链可变区(VL)中含有的3个CDR;或,(b)如SEQ ID NO:12所示的重链可变区(VH)中含有的3个CDR;和/或,如SEQ ID NO:16所示的轻链可变区(VL)中含有的3个CDR;或,优选地,所述VH中含有的3个CDR和/或所述VL中含有的3个CDR由Kabat、IMGT或Chothia编号系统定义。
- 权利要求1所述的抗体或其抗原结合片段,其包含:(a)下述3个重链可变区(VH)的互补决定区(CDRs):序列为SEQ ID NO:1的VH CDR1、序列为SEQ ID NO:2的VH CDR2、序列为SEQ ID NO:3的VH CDR3;和/或,下述3个的轻链可变区(VL)的互补决定区(CDRs):序列为SEQ ID NO:5的VL CDR1、序列为SEQ ID NO:6的VL CDR2、序列为SEQ ID NO:7的VL CDR3;或,(b)下述3个重链可变区(VH)的互补决定区(CDRs):序列为SEQ ID NO:9的VH CDR1、序列为SEQ ID NO:10的VH CDR2、序列为SEQ ID NO:11的VH CDR3;和/或,下述3个轻链可变区(VL)的互补决定区(CDRs):序列为SEQ ID NO:13的VL CDR1、序列为SEQ ID NO:14的VL CDR2、序列为SEQ ID NO:15的VL CDR3; 或,其中,所述CDR由IMGT编号系统定义。
- 权利要求1或2的抗体或其抗原结合片段,所述抗体或其抗原结合片段进一步包含人免疫球蛋白的框架区;例如,所述抗体或其抗原结合片段包含人胚系抗体基因所编码的氨基酸序列中所包含的框架区;例如,所述抗体或其抗原结合片段包含:人重链胚系基因所编码的氨基酸序列中所包含的重链框架区,和/或人轻链胚系基因所编码的氨基酸序列中所包含的轻链框架区。
- 权利要求1-3任一项的抗体或其抗原结合片段,其包含:(a)包含如SEQ ID NO:4所示的序列或其变体的VH,和/或,包含如SEQ ID NO:8所示的序列或其变体的VL;或,(b)包含如SEQ ID NO:12所示的序列或其变体的VH,和/或,包含如SEQ ID NO:16所示的序列或其变体的VL;其中,所述变体与其所源自的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个,2个,3个,4个或5个氨基酸的置换、缺失或添加),或具有至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%、或100%的序列同一性的序列;优选地,所述的置换是保守置换;例如,所述抗体或其抗原结合片段包含如SEQ ID NO:4所示的VH,和/或,如SEQ ID NO:8所示的VL;例如,所述抗体或其抗原结合片段包含如SEQ ID NO:12所示的VH,和/或,如SEQ ID NO:16所示的VL。
- 权利要求1-4任一项所述的抗体或其抗原结合片段,其进一步包含来源于人免疫球蛋白的恒定区;优选地,所述抗体或其抗原结合片段的重链包含来源于人免疫球蛋白(例如IgG1、IgG2、IgG3或IgG4)的重链恒定区;优选地,所述抗体或其抗原结合片段具备ADCC活性;优选地,所述抗体或其抗原结合片段包含突变的或化学修饰的Fc区,其与野生型 Fc区相比提供增加的ADCC活性;优选地,所述抗体或其抗原结合片段是低岩藻糖基化或无岩藻糖基化的;优选地,所述抗体或其抗原结合片段的轻链包含来源于人免疫球蛋白(例如κ或λ)的轻链恒定区。
- 权利要求1-5任一项所述的抗体或其抗原结合片段,其中,所述抗原结合片段选自Fab、Fab’、(Fab’) 2、Fv、二硫键连接的Fv、scFv、双抗体(diabody)和单域抗体(sdAb);和/或,所述抗体为嵌合抗体、双特异性抗体或多特异性抗体。
- 分离的核酸分子,其编码权利要求1-6任一项所述的抗体或其抗原结合片段,或其重链可变区和/或轻链可变区。
- 载体,其包含权利要求7所述的核酸分子;优选地,所述载体为克隆载体或表达载体。
- 宿主细胞,其包含权利要求7所述的核酸分子或权利要求8所述的载体;优选地,所述宿主细胞具有低或无岩藻糖基化活性,例如选自缺乏表达编码岩藻糖基转移酶基因的哺乳动物细胞(例如CHO细胞)。
- 制备权利要求1-6任一项所述的抗体或其抗原结合片段的方法,其包括,在允许所述抗体或其抗原结合片段表达的条件下,培养权利要求9所述的宿主细胞,和从培养的宿主细胞培养物中回收所述抗体或其抗原结合片段;优选地,所述宿主细胞具有低或无岩藻糖基化活性,例如选自缺乏表达编码岩藻糖基转移酶基因的哺乳动物细胞(例如CHO细胞)。
- 药物组合物,其包含权利要求1-6任一项所述的抗体或其抗原结合片段、权利要求7所述的分离的核酸分子、权利要求8所述的载体或权利要求9所述的宿主细胞,以及药学上可接受的载体和/或赋形剂;优选地,所述药物组合物还包含另外的免疫检查点抑制剂;优选地,所述药物组合物还包含抗PD-1抗体或抗PD-L1抗体。
- 权利要求1-6任一项所述的抗体或其抗原结合片段、权利要求7所述的分离的核酸分子、权利要求8所述的载体、权利要求9所述的宿主细胞或权利要求11所述的药物组合物用于制备药物的用途,所述药物用于:(1)在体外或受试者(例如人)体内提高免疫细胞活性;(2)在受试者(例如人)中增强免疫应答;(3)在受试者(例如人)中预防和/治疗肿瘤;或(4)在受试者(例如人)中预防和/治疗感染;优选地,所述免疫细胞是T细胞,和/或,NK细胞;优选地,所述免疫应答是T细胞或NK细胞介导的免疫应答;优选地,所述肿瘤涉及TIGIT阳性的侵润T细胞和/或NK细胞,和/或涉及TIGIT配体(例如CD155和/或CD112)阳性的肿瘤细胞;优选地,所述肿瘤选自实体肿瘤或血液肿瘤(例如,白血病、淋巴瘤、骨髓瘤);优选地,所述肿瘤选自结直肠癌、结肠癌、膀胱癌、乳腺癌、子宫/宫颈癌、卵巢癌、前列腺癌、睾丸癌、食管癌、胃肠癌、胰腺癌、肾癌、头颈癌、肺癌、胃癌、生殖细胞癌、骨癌、肝癌、甲状腺癌、皮肤癌、中枢神经系统的肿瘤、淋巴瘤、白血病、骨髓瘤、肉瘤、黑色素瘤;优选地,所述感染选自病毒感染、细菌感染、真菌感染和寄生虫感染;优选地,所述受试者为哺乳动物,例如人、食蟹猴或小鼠;优选地,所述抗体或其抗原结合片段、分离的核酸分子、载体、宿主细胞或药物组合物单独使用,或与另外的药学活性剂联合使用;优选地,所述另外的药学活性剂是另外的免疫检查点抑制剂;优选地,所述抗体或其抗原结合片段、分离的核酸分子、载体、宿主细胞或药物组合物与抗PD-1抗体或抗PD-L1抗体联合使用。
- 用于在受试者中增强免疫应答或预防和/或治疗肿瘤或感染的方法,其包括:给有此需要的受试者施用有效量的权利要求1-6任一项所述的抗体或其抗原结合片段或权利要求11所述的药物组合物;优选地,所述肿瘤涉及TIGIT阳性的侵润T细胞和/或NK细胞,和/或涉及TIGIT配体(例如CD155和/或CD112)阳性的肿瘤细胞;优选地,所述肿瘤选自实体肿瘤或血液肿瘤(例如,白血病、淋巴瘤、骨髓瘤);优选地,所述肿瘤选自结直肠癌、结肠癌、膀胱癌、乳腺癌、子宫/宫颈癌、卵巢癌、前列腺癌、睾丸癌、食管癌、胃肠癌、胰腺癌、肾癌、头颈癌、肺癌、胃癌、生殖细胞癌、骨癌、肝癌、甲状腺癌、皮肤癌、中枢神经系统的肿瘤、淋巴瘤、白血病、骨髓瘤、肉瘤、黑色素瘤;优选地,所述感染选自病毒感染、细菌感染、真菌感染和寄生虫感染;优选地,所述受试者为哺乳动物,例如人。
- 缀合物,其包含权利要求1-6任一项所述的抗体或其抗原结合片段,以及与所述抗体或其抗原结合片段连接的可检测的标记;优选地,所述可检测的标记选自酶(例如辣根过氧化物酶或碱性磷酸酶)、化学发光试剂(例如吖啶酯类化合物、鲁米诺及其衍生物、或钌衍生物)、荧光染料(例如荧光素或荧光蛋白)、放射性核素或生物素。
- 试剂盒,其包括权利要求1-6任一项所述的抗体或其抗原结合片段或权利要求14所述的缀合物;优选地,所述试剂盒包含权利要求14所述的缀合物;优选地,所述试剂盒包含权利要求1-6任一项所述的抗体或其抗原结合片段,以及特异性识别所述抗体或其抗原结合片段的第二抗体;任选地,所述第二抗体还包括可检测的标记,例如酶(例如辣根过氧化物酶或碱性磷酸酶)、化学发光试剂(例如吖啶酯类化合物、鲁米诺及其衍生物、或钌衍生物)、荧光染料(例如荧光素或荧光蛋白)、放射性核素或生物素。
- 用于检测TIGIT在样品中的存在或其水平的方法,其包括使用权利要求1-6任一项所述的抗体或其抗原结合片段或权利要求14所述的缀合物;优选地,所述方法是免疫学检测,例如免疫印迹法、酶免疫测定法(例如ELISA)、化学发光免疫分析法、荧光免疫分析法或放射免疫测定法;优选地,所述方法包括使用权利要求14所述的缀合物;优选地,所述方法包括使用权利要求1-6任一项所述的抗体或其抗原结合片段,并且所述方法还包括使用携带可检测的标记(例如酶(例如辣根过氧化物酶或碱性磷酸酶)、 化学发光试剂(例如吖啶酯类化合物、鲁米诺及其衍生物、或钌衍生物)、荧光染料(例如荧光素或荧光蛋白)、放射性核素或生物素)的第二抗体来检测所述抗体或其抗原结合片段。
- 权利要求1-6任一项所述的抗体或其抗原结合片段或权利要求14所述的缀合物在制备检测试剂中的用途,所述试剂盒用于检测TIGIT在样品中的存在或其水平;优选地,所述检测试剂通过权利要求16所述的方法来检测TIGIT在样品中的存在或其水平;优选地,所述样品为来自受试者(例如哺乳动物,优选人、食蟹猴或小鼠)的细胞样品(例如,免疫细胞)。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3228504A CA3228504A1 (en) | 2021-08-09 | 2022-08-09 | Anti-tigit antibody and use thereof |
EP22855431.7A EP4386003A1 (en) | 2021-08-09 | 2022-08-09 | Anti-tigit antibody and use thereof |
AU2022327511A AU2022327511A1 (en) | 2021-08-09 | 2022-08-09 | Anti-tigit antibody and use thereof |
JP2024508052A JP2024533993A (ja) | 2021-08-09 | 2022-08-09 | 抗tigit抗体およびその使用 |
CN202280054124.0A CN117794952A (zh) | 2021-08-09 | 2022-08-09 | 抗tigit抗体及其用途 |
KR1020247007621A KR20240043786A (ko) | 2021-08-09 | 2022-08-09 | 항-tigit 항체 및 이의 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110907583 | 2021-08-09 | ||
CN202110907583.6 | 2021-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023016450A1 true WO2023016450A1 (zh) | 2023-02-16 |
Family
ID=85199833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/111145 WO2023016450A1 (zh) | 2021-08-09 | 2022-08-09 | 抗tigit抗体及其用途 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4386003A1 (zh) |
JP (1) | JP2024533993A (zh) |
KR (1) | KR20240043786A (zh) |
CN (1) | CN117794952A (zh) |
AU (1) | AU2022327511A1 (zh) |
CA (1) | CA3228504A1 (zh) |
WO (1) | WO2023016450A1 (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
WO2010105256A1 (en) | 2009-03-13 | 2010-09-16 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
WO2012009568A2 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Antibody libraries |
CA3042727A1 (en) * | 2016-11-19 | 2018-05-24 | Potenza Therapeutics, Inc. | Anti-gitr antigen-binding proteins and methods of use thereof |
CN112135626A (zh) * | 2018-07-25 | 2020-12-25 | 信达生物制药(苏州)有限公司 | 抗tigit抗体及其用途 |
US20200407445A1 (en) * | 2017-07-27 | 2020-12-31 | Iteos Therapeutics Sa | Anti-tigit antibodies |
CN112274637A (zh) * | 2016-08-17 | 2021-01-29 | 康姆普根有限公司 | 抗tigit抗体、抗pvrig抗体及其组合 |
CN112794909A (zh) * | 2021-02-04 | 2021-05-14 | 广州爱思迈生物医药科技有限公司 | 一种抗tigit单克隆抗体及其应用 |
-
2022
- 2022-08-09 CN CN202280054124.0A patent/CN117794952A/zh active Pending
- 2022-08-09 EP EP22855431.7A patent/EP4386003A1/en active Pending
- 2022-08-09 CA CA3228504A patent/CA3228504A1/en active Pending
- 2022-08-09 WO PCT/CN2022/111145 patent/WO2023016450A1/zh active Application Filing
- 2022-08-09 KR KR1020247007621A patent/KR20240043786A/ko unknown
- 2022-08-09 JP JP2024508052A patent/JP2024533993A/ja active Pending
- 2022-08-09 AU AU2022327511A patent/AU2022327511A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
WO2010105256A1 (en) | 2009-03-13 | 2010-09-16 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
WO2012009568A2 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Antibody libraries |
CN112274637A (zh) * | 2016-08-17 | 2021-01-29 | 康姆普根有限公司 | 抗tigit抗体、抗pvrig抗体及其组合 |
CA3042727A1 (en) * | 2016-11-19 | 2018-05-24 | Potenza Therapeutics, Inc. | Anti-gitr antigen-binding proteins and methods of use thereof |
US20200407445A1 (en) * | 2017-07-27 | 2020-12-31 | Iteos Therapeutics Sa | Anti-tigit antibodies |
CN112135626A (zh) * | 2018-07-25 | 2020-12-25 | 信达生物制药(苏州)有限公司 | 抗tigit抗体及其用途 |
CN112794909A (zh) * | 2021-02-04 | 2021-05-14 | 广州爱思迈生物医药科技有限公司 | 一种抗tigit单克隆抗体及其应用 |
Non-Patent Citations (37)
Title |
---|
ALFTHAN ET AL., PROTEIN ENG., vol. 8, 1995, pages 725 - 731 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 |
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426 |
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 |
BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187 |
BURKS ET AL., PROC. NATL ACAD. SET USA, vol. 94, 1997, pages 412 - 417 |
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167 |
CHOI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 94 - 106 |
CHOTHIA ET AL., NATURE, vol. 341, 1989, pages 544 - 546 |
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
DAVIES ET AL., ANNUAL REV BIOCHEM, vol. 59, 1990, pages 439 - 473 |
ESTE, P ET AL.: "High throughput solution-based measurement of antibody-antigen affinity and epitope binning", MABS, vol. 5, no. 2, 2013, pages 270 - 8, XP055105281, DOI: 10.4161/mabs.23049 |
F. M. AUSUBEL ET AL.: "Compiled Laboratory Guide to Molecular Biology", 1995, JOHN WILEY & SONS, INC. |
GE, ZHOUHONG ET AL.: "TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer", FRONTIERS IN IMMUNOLOGY, vol. 12, 22 July 2021 (2021-07-22), XP055973881, DOI: 10.3389/fimmu.2021.699895 * |
GUILLEREY CHARJUNPAA HCARRIE N ET AL.: "TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma", BLOOD, vol. 132, 2018, pages 1689 - 1694, XP086685467, DOI: 10.1182/blood-2018-01-825265 |
HOLLIGER ET AL., NAT BIOTECHNOL, vol. 23, 2005, pages 1126 - 1136 |
HOLLIGER P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448 |
HU ET AL., CANCER RES., vol. 56, 1996, pages 3055 - 3061 |
HUDSON, CURR. OPIN. IMMUNOL., vol. 11, 1999, pages 548 - 557 |
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883 |
J. SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
JOHNSTON ROBERT J.; COMPS-AGRAR LAETITIA; HACKNEY JASON; YU XIN; HUSENI MAHRUKH; YANG YAGAI; PARK SUMMER; JAVINAL VINCENT; CHIU HE: "The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+T Cell Effector Function", CANCER CELL, vol. 26, no. 6, 26 November 2014 (2014-11-26), US , pages 923 - 937, XP029111576, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2014.10.018 * |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE |
KARLINALTSCHUL, PROC. NATL. ACAD. SCI. U.S.A., vol. 87, 1990, pages 2264 - 2268 |
KARLINALTSCHUL, PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 5873 - 5877 |
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56 |
KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884 |
KURTULUS SSAKUISHI KNGIOW SF ET AL.: "TIGIT predominantly regulates the immune response via regulatory T cells", J CLIN INVEST., vol. 125, no. 11, 2 November 2015 (2015-11-02), pages 4053 - 62, XP055708798, DOI: 10.1172/JCI81187 |
LEFRANC ET AL., DEV. COMPARAT. IMMUNOL., vol. 27, 2003, pages 55 - 77 |
LITTLE ET AL., IMMUNOL. TODAY, vol. 21, 2000, pages 364 - 370 |
MALMQVIST M, NATURE, vol. 361, 1993, pages 186 - 187 |
MORIMOTO ET AL., J. BIOCHEM. BIOPHYS. METHODS, vol. 24, 1992, pages 107 - 117 |
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
POLJAK R. J. ET AL., STRUCTURE, vol. 113, 1994, pages 1121 - 1123 |
ROOVERS ET AL., CANCER IMMUNOL, 2001 |
ZHANG QBI JZHENG X ET AL.: "Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity", NAT IMMUNOL., vol. 19, no. 7, July 2018 (2018-07-01), pages 723 - 732, XP036533618, DOI: 10.1038/s41590-018-0132-0 |
ZHU LINXIAO, LI YOULUN: "Clinical Research Status of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer", JOURNAL OF CLINICAL PULMONARY MEDICINE, vol. 25, no. 5, 23 April 2020 (2020-04-23), pages 788 - 793, XP093034251, ISSN: 1009-6663 * |
Also Published As
Publication number | Publication date |
---|---|
KR20240043786A (ko) | 2024-04-03 |
JP2024533993A (ja) | 2024-09-18 |
CN117794952A (zh) | 2024-03-29 |
CA3228504A1 (en) | 2023-02-16 |
AU2022327511A1 (en) | 2024-03-07 |
EP4386003A1 (en) | 2024-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7269215B2 (ja) | 抗cd3抗体、抗cd123抗体及びcd3及び/又はcd123に特異的に結合する二重特異性抗体 | |
CN112074536B (zh) | 用于肿瘤特异性细胞清除的抗-cd25 | |
CN112142847B (zh) | 改造的Fc片段,包含其的抗体及其应用 | |
WO2018147245A1 (ja) | 抗gprc5d抗体及び該抗体を含む分子 | |
US20230192840A1 (en) | Antibody and use thereof | |
CN110734493B (zh) | 抗pd-1抗体及其用途 | |
US20230416394A1 (en) | Novel conjugate molecules targeting cd39 and tgfbeta | |
EP4421095A1 (en) | Anti-mesothelin nanobodies and use thereof | |
CN116209680A (zh) | 与人CD3ε结合的新型人抗体 | |
CN115043942A (zh) | Ror1结合蛋白及其用途 | |
WO2022100694A1 (zh) | 抗体及其制备方法 | |
WO2023016450A1 (zh) | 抗tigit抗体及其用途 | |
WO2023236951A1 (zh) | 抗cd40抗体及其用途 | |
WO2024094003A1 (zh) | 抗ccr8的抗体及其用途 | |
WO2024114525A1 (zh) | B7-h3结合蛋白及其用途 | |
WO2023186121A1 (en) | Anti-cd39 nanobody and uses thereof | |
WO2024061224A1 (zh) | 抗her2抗体及其用途 | |
US20220162305A1 (en) | Antibodies having specificity for btn2 and uses thereof | |
WO2023165475A9 (zh) | Her3结合蛋白及其用途 | |
WO2022188652A1 (zh) | Ror1结合蛋白及其用途 | |
WO2024007671A1 (zh) | 特异性结合cd24的抗体及其用途 | |
WO2024094159A1 (zh) | 靶向人源ror1的单域抗体 | |
WO2024131956A1 (zh) | 靶向gprc5d的多特异性多肽复合物 | |
US20240317880A1 (en) | Epithelial Cadherin-Specific Antibodies | |
TW202417516A (zh) | Ptk7結合蛋白及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22855431 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280054124.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2024508052 Country of ref document: JP Ref document number: 3228504 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022327511 Country of ref document: AU Ref document number: AU2022327511 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024002596 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022327511 Country of ref document: AU Date of ref document: 20220809 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022855431 Country of ref document: EP Effective date: 20240311 |
|
ENP | Entry into the national phase |
Ref document number: 112024002596 Country of ref document: BR Kind code of ref document: A2 Effective date: 20240208 |